RU2017136047A - Composition for the treatment of Parkinson's disease - Google Patents
Composition for the treatment of Parkinson's disease Download PDFInfo
- Publication number
- RU2017136047A RU2017136047A RU2017136047A RU2017136047A RU2017136047A RU 2017136047 A RU2017136047 A RU 2017136047A RU 2017136047 A RU2017136047 A RU 2017136047A RU 2017136047 A RU2017136047 A RU 2017136047A RU 2017136047 A RU2017136047 A RU 2017136047A
- Authority
- RU
- Russia
- Prior art keywords
- pharmaceutical composition
- dosage form
- composition described
- finished
- cryoprotectant
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
- A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
- A61K31/216—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acids having aromatic rings, e.g. benactizyne, clofibrate
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
- A61K47/34—Macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyesters, polyamino acids, polysiloxanes, polyphosphazines, copolymers of polyalkylene glycol or poloxamers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/44—Oils, fats or waxes according to two or more groups of A61K47/02-A61K47/42; Natural or modified natural oils, fats or waxes, e.g. castor oil, polyethoxylated castor oil, montan wax, lignite, shellac, rosin, beeswax or lanolin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/10—Dispersions; Emulsions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Medicinal Chemistry (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- General Chemical & Material Sciences (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Biomedical Technology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Psychology (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Inorganic Chemistry (AREA)
- Emergency Medicine (AREA)
- Dispersion Chemistry (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicinal Preparation (AREA)
Claims (5)
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
RU2017136047A RU2697411C2 (en) | 2017-10-11 | 2017-10-11 | Composition for treating parkinson's disease |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
RU2017136047A RU2697411C2 (en) | 2017-10-11 | 2017-10-11 | Composition for treating parkinson's disease |
Publications (3)
Publication Number | Publication Date |
---|---|
RU2017136047A3 RU2017136047A3 (en) | 2019-04-11 |
RU2017136047A true RU2017136047A (en) | 2019-04-11 |
RU2697411C2 RU2697411C2 (en) | 2019-08-14 |
Family
ID=66167982
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
RU2017136047A RU2697411C2 (en) | 2017-10-11 | 2017-10-11 | Composition for treating parkinson's disease |
Country Status (1)
Country | Link |
---|---|
RU (1) | RU2697411C2 (en) |
Families Citing this family (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN115707462A (en) * | 2021-08-19 | 2023-02-21 | 沈阳药科大学 | Levodopa composition for improving brain targeting and application thereof |
Family Cites Families (8)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4610868A (en) * | 1984-03-20 | 1986-09-09 | The Liposome Company, Inc. | Lipid matrix carriers for use in drug delivery systems |
US5229130A (en) * | 1991-12-20 | 1993-07-20 | Cygnus Therapeutics Systems | Vegetable oil-based skin permeation enhancer compositions, and associated methods and systems |
DE69940735D1 (en) * | 1998-07-17 | 2009-05-28 | Pacira Pharmaceuticals Inc | BIODEGRADABLE ARRANGEMENTS FOR THE CONTROLLED RELEASE OF INCLUDED SUBSTANCES |
AU764742B2 (en) * | 1998-11-10 | 2003-08-28 | Teva Pharmaceutical Industries Ltd. | Dispersible compositions containing L-DOPA ethyl ester |
US6696600B2 (en) * | 2001-11-13 | 2004-02-24 | Teva Pharmaceutical Industries, Ltd. | L-DOPA ethyl ester salts and uses thereof |
US7160913B2 (en) * | 2002-09-13 | 2007-01-09 | Thomas Jefferson University | Methods and kit for treating Parkinson's disease |
JP2008534563A (en) * | 2005-03-28 | 2008-08-28 | オレクソ・アクチエボラゲット | New pharmaceutical compositions useful for the treatment of Parkinson's disease |
RU2545734C1 (en) * | 2014-01-31 | 2015-04-10 | Открытое акционерное общество "Всероссийский Научный Центр Молекулярной Диагностики и Лечения" (ОАО "ВНЦМДЛ) | Drug preparation for parkinson disease |
-
2017
- 2017-10-11 RU RU2017136047A patent/RU2697411C2/en active
Also Published As
Publication number | Publication date |
---|---|
RU2017136047A3 (en) | 2019-04-11 |
RU2697411C2 (en) | 2019-08-14 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
AU2020220142B2 (en) | Low molecular weight silk compositions and stabilizing silk compostions | |
US11376329B2 (en) | Low molecular weight silk compositions and stabilizing silk compositions | |
CL2017001115A1 (en) | Stable formulation of protein in solution that contains a high concentration of an anti-vegf antibody. | |
EA201892173A1 (en) | PHARMACEUTICAL COMPOSITION OF PALBOCYCLIBE AND METHOD FOR PRODUCING IT | |
EP3763703A3 (en) | Novel crystalline forms of {[5-(3-chlorophenyl)-3-hydroxypyridine-2-carbonyl]amino}acetic acid and processes for preparation thereof | |
Ryu et al. | Dry tablet formulation of PLGA nanoparticles with a preocular applicator for topical drug delivery to the eye | |
CY1120891T1 (en) | PHARMACEUTICAL COMPOSITION OF SLOW RELEASE MADE MADE OF MICROPARTICLES | |
JP2017519568A5 (en) | ||
EA201791537A1 (en) | PHARMACEUTICAL COMPOSITION ON THE BASIS OF NANOPARTICLES OF DOCETAXEL-ALBUMIN, METHOD FOR ITS PREPARATION AND ITS APPLICATION | |
Amato et al. | Local delivery and controlled release drugs systems: a new approach for the clinical treatment of periodontitis therapy | |
CA2926169A1 (en) | Continuous release compositions made from hyaluronic acid, and therapeutic applications of same | |
CN107982239A (en) | Hydrophobic drug crystal is the aspherical micro-capsule of albumen base and preparation method of template | |
RU2017136047A (en) | Composition for the treatment of Parkinson's disease | |
ES2947659T3 (en) | Processing method for biopolymers using solvent combinations | |
EA202092922A1 (en) | PHARMACEUTICAL COMPOSITION WITH IMPROVED SOLUBILITY AND BIOLOGICAL AVAILABILITY | |
BR112018008769A2 (en) | pharmaceutical formulations, reconstituted and lyophilized aqueous liquid formulations, syringe, method of manufacturing a pharmaceutical formulation, method for treating a disease and use of a reconstructed formulation | |
RU2017137314A (en) | METHOD FOR OBTAINING A PHARMACEUTICAL COMPOSITION CONTAINING PENTOXYFILLIN | |
Babu et al. | Aripiprazole loaded PLGA nanoparticles for controlled release studies: Effect of Co-polymer ratio | |
EA201700521A2 (en) | METHOD OF OBTAINING A NATIVE PROTECTION PROTECTIVE PROTEIN ACTION IN THE COMPOSITION OF POLYMERIC NANOSPHERE AND RECESSED MICROSPHERE FOR DELIVERY | |
EA043753B1 (en) | BIOADHESIVE ANTIBACTERIAL AGENT, METHOD OF ITS MANUFACTURE (OPTIONS) | |
RU2649743C1 (en) | Liquid dosage form containing drug substance placed in biodegradable polymers | |
CL2022002193A1 (en) | Formulations of human anti-tslp antibodies and methods of treatment of an inflammatory disease | |
UA119632C2 (en) | METHOD OF OBTAINING SOLID DISPERSIONS OF INSOLUBLE SUBSTANCES IN AQUATIC ENVIRONMENT | |
RU2017122775A (en) | The treatment for female infertility and infertility of female animals | |
RU2013154071A (en) | MEDICINAL PRODUCT AND METHOD FOR TREATMENT OF HEAD-WAYS |